Linda A. Hill is the Wallace Brett Donham Professor of Business Administration at the Harvard Business School and chair of the Leadership Initiative. Prof. Hill is regarded as one of the top experts on leadership and innovation, and is the co-author of Collective Genius: The Art and Practice of Leading Innovation (Harvard Business Review Press 2014), co-founder of Paradox Strategies, and co-creator of the Innovation Quotient and re:Route. She was named by Thinkers50 as one of the top ten management thinkers in the world in 2013 and 2021 and received the Thinkers50 Innovation Award in 2015.
Hill’s research focuses on leadership development, building agile, innovative organizations, and implementing global strategies. She is the author of highly regarded books and articles on leadership. Collective Genius was named by Business Insider as one of “The 20 Best Business Books” and received the Gold Medal for Leadership, Axiom Business Book Award. In 2015, Hill, along with her co-authors, received the first Warren Bennis Prize for the Harvard Business Review article “Collective Genius,” based on the book. Hill is also the co-author of Being the Boss: The 3 Imperatives of Becoming a Great Leader and author of Becoming a Manager: How New Managers Master the Challenges of Leadership. Her books have been translated in multiple languages.
Hill is a member of the Board of Directors of Relay Therapeutics and is on the Board of Trustees of the ArtCenter College of Design and of Brigham Health. She is also a member of the Team8 Fintech Strategic Committee and she serves on the advisory boards of several organizations including the American Repertory Theater, the Aspen Institute Business and Society Program, the California Institute for Telecommunications and Information Technology (Calit2), Eight Inc., the Morgan Stanley Institute for Sustainable Investing, and the United Nations Institute for Training and Research. She sits on the board of the Global Citizens Initiative, Inc. and is a Special Representative to the Board of Trustees of Bryn Mawr College. Hill is a former member of the Board of Directors of Harvard Business Publishing, State Street Corporation, The Bridgespan Group, and the Eaton Corporation. She is also a former member of the Board of Trustees of The Rockefeller Foundation and the Nelson Mandela Children's Fund USA.
Hill’s consulting and executive education activities have been in the areas of leadership development, talent management, leading change and innovation, implementing global strategies, managing cross-organizational relationships, and diversity and inclusion. Organizations with which Professor Hill has worked include the Abu Dhabi Investment Authority, Accenture, AREVA, IBM, MasterCard, Merck, Mitsubishi, Morgan Stanley, National Bank of Kuwait, The Federal Reserve Bank, NASA, RELX, UnitedHealth Group, The Economist, Salesforce.com, and The World Economic Forum.
Hill completed a post-doctoral research fellowship at the Harvard Business School and earned a Ph.D. in Behavioral Sciences at the University of Chicago. She received her M.A. in Educational Psychology from the University of Chicago. She has a B.A., summa cum laude, in psychology from Bryn Mawr College.
To use this function, you need to be signed in
with a personal account.
If you already have a personal account, please
login here.
Otherwise you may sign up now
for a personal account.
Cookies and Privacy
We use cookies, and similar tools, to improve the way this site functions, to
track browsing patterns and enable marketing. For more information read our
cookie policy and
privacy policy.
Some types of cookies can be disabled by you but doing so may adversely
affect functionality. Please see below:
(always on)
If you block these cookies or set alerts in your browser parts
of the website will not work.
Cookies that provide enhanced functionality and personalisation. If not
allowed functionality may be impaired.
Cookies that count and track visits and on website activity enabling us
to organise the website to optimise the experience of users. They may be
blocked without immediate adverse effect.